Argenx Se (ARGX) Interest & Investment Income (2016 - 2026)
Argenx Se's (ARGX) quarterly Interest & Investment Income came in at $48.0 million in Q2 2026, up 25.0% YoY from $38.4 million in Q2 2025, and up 9.09% on a QoQ basis from $44.0 million in Q1 2026.
Argenx Se (ARGX) Interest & Investment Income (2016 - 2026) Analysis & Trends
Argenx Se (ARGX) has 11 years of Interest & Investment Income data on file, last reported at $48.0 million in Q2 2026.
- Quarterly Interest & Investment Income rose 25.0% year-over-year to $48.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $179.6 million (up 15.79% YoY) and the FY2025 annual result came in at $163.1 million, up 3.54% from the prior year.
- Interest & Investment Income advanced to $48.0 million in Q2 2026, from $44.0 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $48.0 million in Q2 2026 to a low of $821000.0 in Q1 2022.
- A 5-year average of $30.4 million and a median of $38.6 million in 2024 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2023 — Interest & Investment Income soared 1920.46% — and 2025, when it retreated 4.87%.
- Tracing ARGX's Interest & Investment Income over 5 years: stood at $13.9 million in 2022, then soared by 189.46% to $40.3 million in 2023, then dropped by 3.01% to $39.1 million in 2024, then climbed by 14.78% to $44.9 million in 2025, then climbed by 6.97% to $48.0 million in 2026.
- The last three Interest & Investment Income figures came in at $48.0 million (Q2 2026), $44.0 million (Q1 2026), and $44.9 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 36.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 48.00 Mn |
| Mar 31, 2026 | 44.00 Mn |
| Dec 31, 2025 | 44.87 Mn |
| Sep 30, 2025 | 42.70 Mn |
| Jun 30, 2025 | 38.40 Mn |
| Mar 31, 2025 | 37.00 Mn |
| Dec 31, 2024 | 39.10 Mn |
| Sep 30, 2024 | 40.59 Mn |
| Jun 30, 2024 | 38.93 Mn |
| Mar 31, 2024 | 38.90 Mn |
| Dec 31, 2023 | 40.31 Mn |
| Sep 30, 2023 | 30.05 Mn |
| Jun 30, 2023 | 20.44 Mn |
| Mar 31, 2023 | 16.59 Mn |
| Dec 31, 2022 | 13.93 Mn |
| Sep 30, 2022 | 8.01 Mn |
| Jun 30, 2022 | 4.91 Mn |
| Mar 31, 2022 | 821,000.00 |
| Dec 31, 2021 | 1.20 Mn |
| Sep 30, 2021 | 805,000.00 |